| Literature DB >> 26914883 |
Jerry Natenstedt1, Aimee C Kok2, Jenny Dankelman3, Gabrielle Jm Tuijthof4,5.
Abstract
Articular cartilage has limited regeneration capacities. One of the factors that appear to affect the in vitro cultivation of articular cartilage is mechanical stimulation. So far, no combination of parameters has been identified that offers the best results. The goal is to review the literature in search of the best available set of quantitative mechanical stimuli that lead to optimal in vitro cultivation.The databases Scopus and PubMed were used to survey the literature, and strict in- and exclusion criteria were applied regarding the presence of quantitative data. The review was performed by studying the type of loading (hydrostatic compression or direct compression), the loading magnitude, the frequency and the loading regime (duration of the loading) in comparison to quantitative evidence of cartilage quality response (cellular, signaling and mechanical).Thirty-three studies met all criteria of which 8 studied human, 20 bovine, 2 equine, 1 ovine, 1 porcine and 1 canine cells using four different types of cultivated constructs. Six studies investigated loading magnitude within the same setup, three studies the frequency, and seven the loading regime. Nine studies presented mechanical tissue response. The studies suggest that a certain threshold exits for enhanced cartilage in vitro cultivation of explants (>20 % strain and 0.5 Hz), and that chondrocyte-seeded cultivated constructs show best results when loaded with physiological mechanical stimuli. That is a loading pressure between 5-10 MPa and a loading frequency of 1 Hz exerted at intermittent intervals for a period of a week or longer. Critical aspects remain to be answered for translation into in vivo therapies.Entities:
Keywords: BMMSC; Cell therapy; Chondrocytes; Collagen type II; Compression; GAG; Mechanical loading; in vitro
Year: 2015 PMID: 26914883 PMCID: PMC4538712 DOI: 10.1186/s40634-015-0029-x
Source DB: PubMed Journal: J Exp Orthop ISSN: 2197-1153
Fig. 1Cellular structure of cartilage. Defects are sustained in different layers: partial thickness chondral defect (up till the deep zone), full thickness chondral defect (up till the calcified cartilage) and osteochondral defect (crossing the subchondral bone plate) base on (Madry et al. 2010)
Results on changes in cellular, signaling and/or mechanical response to explants for hydrostatic and direct compression (Fig. 2). PG is proteoglycan; MMP is matrix metalloproteinases; # is number; h is hours; h/day is hours per day; − is decrease or inhibition; = is no change or status quo; + is increase; ++ is highest increase. *-symbol implies pressure converted from strain, which is added in brackets
| Study | Cell source, cultivated construct, additive(s) | Magnitude (MPa) | Freq (Hz) | Loading (h/day) | Loading (# days) | Loading (total h) | Culture composition (change -, =, +) | mRNA response (change -, =, +) | Other findings (change -, =, +) |
|---|---|---|---|---|---|---|---|---|---|
| Hydrostatic compression | |||||||||
| Parkinnen 1993 (Parkkinen et al. | Bovine | 5 | 0.5 | 1.5 | 1 | 1.5 | + PG synthesis | ||
| Explant | 0.25 | ||||||||
| Fetal calf serum | 0.05 | = PG synthesis | |||||||
| 0.0167 | |||||||||
| Direct compression | |||||||||
| Li 2013 (Li et al. | Young Bovine Bruised Explant Serum free medium, 20 g/ml ascorbic acid | 0.6-1.2* (10 %) | 0.5 | 4 | 4 | 16 | + PG synthesis | + aggrecan | Control show better results compared to bruised explants |
| + collagen II | |||||||||
| 1.2-2.4* (20 %) | ++ PG synthesis | ++ aggrecan | |||||||
| ++ collagen II | |||||||||
| 1.8-3.6* (30 %) | + PG synthesis | + aggrecan | |||||||
| = collagen II | |||||||||
| Okuda 2013 (Okuda et al. | Young Bovine, Explant 20 % Fetal bovine serum; 50 mg/L L-ascorbic acid | 0.6-1.2* (10 %) | 1 | 3.5 | 5 | 17.5 | + sGAG | + compressive modulus | |
| + # of cells | |||||||||
| Torzilli 1996 (Torzilli et al. | Bovine, Explant 10 % Fetal bovine serum; 50 μg/mL ascorbic acid | 1 | 1 | 24 | 1 | 24 | - PG synthesis | ||
| Torzilli 2011 (Torzilli et al. | Bovine, Explant 10 % Fetal bovine serum; 50 μg/mL ascorbic acid | 0.5 (10 %) | 0.5 | 24 | 3 | 72 | = PG content | = MMP −3, −13 | |
Results on changes in cellular, signaling and/or mechanical response to chondrocyte-seeded meshes for hydrostatic and direct compression (Fig. 2). PGA is polyglycolic acid; PEGT/PBT is polyethylene glycol terephthalate/polybutylene terephthalate; Sox9 is the gene that regulates chondrogenic differentiation; # is number; h is hours; h/day is hours per day; − is decrease or inhibition; = is no change or status quo; + is increase; ++ is highest increase. *-symbol implies pressure converted from strain, which is added in brackets; **loading was performed every other day for 1 h twice a day with 8 h rest in between
| Study | Cell source, cultivated construct, additive(s) | Magnitude (MPa) | Freq (Hz) | Loading (h/day) | Loading (# days) | Loading (total h) | Culture composition (change -, =, +) | mRNA response (change -, =, +) | Other findings (change -, =, +) |
|---|---|---|---|---|---|---|---|---|---|
| Hydrostatic compression | |||||||||
| Carver 1999a (Carver and Heath | Young equine Mesh nonwoven PGA 10 % Fetal bovine serum; 50 μg/mL ascorbic acid | 3.4 | 0.25 | 2 | 35 | 70 | + GAG | GAG increase strongest at 6.9 MPa for young | |
| = collagen II | |||||||||
| = # of chondrocytes | |||||||||
| 6.9 | + GAG | ||||||||
| + collagen II | |||||||||
| = # of chondrocytes | |||||||||
| Adult equine Mesh nonwoven PGA 10 % Fetal bovine serum; 50 μg/mL ascorbic acid | 3.4 | + GAG | Collagen II increase strongest at 6.9 MPa for young and adult | ||||||
| + collagen II | |||||||||
| = # of chondrocytes | |||||||||
| 6.9 | = GAG | ||||||||
| + collagen II | |||||||||
| = # of chondrocytes | |||||||||
| Carver 1999b (Carver and Heath | Young equine Mesh nonwoven PGA 10 % Fetal bovine serum; 50 μg/mL ascorbic acid | 3.44 | 0.25 | 2 | 35 | 70 | + GAG | + E- modulus | |
| + collagen | |||||||||
| = # of chondrocytes | |||||||||
| Direct compression | |||||||||
| Démarteau 2003 (Démarteau et al. | Human Mesh PEGT/PBT Foam 10 % Fetal bovine serum; growth factor TGF-β1, FGF-2, PDGFbb | 0.3-0.6* (5 %) | 0.1 | 4 | 3 | 12 | + GAG | = Sox9 | Measured peak loading 0.018 MPa |
| = aggrecan | |||||||||
| = collagen II | |||||||||
| Hilz 2014 (Hilz et al. | Bovine, Mesh Polyurethane 25 % Fetal calf serum;50 μg/mL L-ascorbic acid | 1.2-2.4* (20 %) | 1 | 2** | 21 | 16 | + GAG | =Sox9 | |
| + aggrecan | +collagen II | ||||||||
| + collagen II | |||||||||
| El-ayoubi 2011 (El-Ayoubi et al. | Canine, Mesh poly-L-Lactide 10 % Fetal bovine serum | 0.6-1.2* (10 %) | 1 | 3 | 14 | 42 | + # of cells | ||
Results on changes in cellular, signaling and/or mechanical response to chondrocyte cultivated constructs for hydrostatic compression (Fig. 2). PG is proteoglycan; MMP is matrix metalloproteinases; h is hours; h/day is hours per day;;- is decrease or inhibition; + is increase; ++ is highest increase; = is no change or status quo. *-symbol implies pressure converted from strain, which is added in brackets, **-symbol is increased aggrecan only with 4 h
| Study | Cell source, cultivated construct, additive(s) | Magnitude (MPa) | Freq (Hz) | Loading (h/day) | Loading (# days) | Loading (total h) | Culture composition (change -, =, +) | mRNA response (change -, =, +) | Other findings (change -, =, +) |
|---|---|---|---|---|---|---|---|---|---|
| Ikenoue 2003 | Human Monolayer 10 % Fetal bovine serum | 1 | 1 | 4 | 1 | 4 | = aggrecan | Loading of 16h gave better results compared to 4h | |
| = collagen II | |||||||||
| 5 | 1 | + aggrecan | |||||||
| 10 | = collagen II | ||||||||
| 1 | 1 | 4 | 4 | 16 | + aggrecan | ||||
| + collagen II | |||||||||
| 5 | 1 | + aggrecan | |||||||
| ++ collagen II | |||||||||
| 10 | 1 | ++ aggrecan | |||||||
| ++ collagen II | |||||||||
| Elder 2008 | Young bovine, Agarose gel, 20 % Fetal bovine serum; 50 μg/mL L-ascorbic acid | 1 | 0.1 | 1 | 5 | 5 | + GAG | = Aggregate modulus | |
| = collagen II and # of cells | = E-modulus | ||||||||
| 5 | 0.1 | = GAG | + Aggregate modulus | ||||||
| = collagen II and # of cells | = E-modulus | ||||||||
| 10 | 0.1 | + GAG | = Aggregate modulus | ||||||
| = collagen II and # of cells | ++ E-modulus | ||||||||
| 1 | 1 | = GAG | + Aggregate modulus | ||||||
| = collagen II and # of cells | + E-modulus | ||||||||
| 5 | 1 | = GAG | = Aggregate modulus | ||||||
| = collagen II and # of cells | = E-modulus | ||||||||
| 10 | 1 | ++ GAG | ++ Aggregate modulus | ||||||
| = collagen II and # of cells | ++ E-modulus | ||||||||
| Hu 2006 | Young bovine, Agarose gel, 10 % Fetal bovine serum; 50 μg/mL L-ascorbic acid | 10 | 1 | 4 | 40 | 160 | = GAG (no loss) + collagen II | = Aggregate modulus | |
| Mizuno 2011 | Young bovine, Aggregate pellet, Collagen solution, 10 % Fetal bovine serum | 0.5 | 0.5 | 24 | 7 | 168 | + sGAG | + aggrecan, + collagen II, + MMP-3, −13 | |
| Kawanishi 2007 | Young bovine, Aggregate pellet, 10 % Fetal bovine serum; 50μg/mL ascorbic acid | 5 | 0.5 | 4 | 4 | 16 | + GAG | + aggrecan | |
| + sGAG | + collagen II | ||||||||
| Suh 1999 | Bovine, Monolayer, 10 % Fetal bovine serum | −0.08 vacuum | 0.14 | 6 | 1 | 6 | + PG synthesis | + aggrecan | |
| = collagen synthesis | = collagen II | ||||||||
| Parkinnen 1993 | Bovine, Monolayer, 10 % Fetal calf serum | 5 | 0.5 | 1.5 | 1 | 1.5 | - PG synthesis | ||
| 0.25 | |||||||||
| 0.05 | |||||||||
| 0.0167 | = PG synthesis | ||||||||
| 0.5 | 20 | 1 | 20 | + PG synthesis | |||||
| 0.25 | |||||||||
| 0.05 | = PG synthesis | ||||||||
| 0.0167 | - PG synthesis | ||||||||
| 0.0082 | = PG synthesis | ||||||||
| 0.0034 | |||||||||
| Jortikka 2000 | Bovine, Monolayer, 10 % Fetal bovine serum | 5 | 0.5 | 20 | 1 | 20 | + PG synthesis | ||
| Smith 1996 | Bovine, Monolayer Ham’s F-12 medium; 3 % Fetal bovine serum | 10 | 1 | 4 | 1 | 4 | + PG synthesis | + aggrecan | |
| + collagen II | |||||||||
| Smith 2000 | Bovine, Monolayer, Ham’s F-12 medium | 10 | 1 | 2,4,8,12, 24 | 1 | 2,4,8,12, 24 | + aggrecan**, + collagen II | Superior increase compared to one loading period | |
| 4 | 4 | 16 | ++ aggrecan, ++ collagen II | ||||||
| Heyland 2006 | Porcine chondrocytes, Beads alginate, 10 % Fetal bovine serum | 0.3 | 0.0083 | 6 | 4 | 24 | + GAG, = collagen II | ||
| 6 | 7 | 42 | = GAG, + collagen II | = E-modulus |
Results on changes in cellular, signaling and/or mechanical response to chondrocyte cultivated constructs for direct compression (Fig. 2). OA is osteoarthritis; MMP is matrix metalloproteinases; PG is proteoglycan; h is hours; h/day is hours per day; − is decrease or inhibition; + is increase; ++ is highest increase; = is no change or status quo. *-symbol implies pressure converted from strain, which is added in brackets,** -symbol is increase only present 12 h post stimulation, ^-symbol is increase only present after 6 h post stimulation
| Study | Cell source, cultivated construct, additive(s) | Magnitude (MPa) | Freq (Hz) | Loading (h/day) | Loading (# days) | Loading (total h) | Culture composition (change -, =, +) | mRNA response (change -, =, +) | Other findings (change -, =, +) |
|---|---|---|---|---|---|---|---|---|---|
| Nebelung 2012 (Nebelung et al. | Human OA Hydrogel collagen type I 10 % Human serum | 0.6-1.2* (10 %) | 0.3 | 24 | 28 | 672 | = proteoglycan | = aggrecan | = E-modulus |
| = collagen II | + collagen II | ||||||||
| + MMP-13 | |||||||||
| Shelton 2003 (Shelton et al. | Bovine, Agarose gel Type VII 20 % Fetal calf serum | 1.7-2.9* (15 %) | 0.3 | 24 | 2 | 48 | - GAG | ||
| 1 | + GAG | ||||||||
| 3 | = GAG | ||||||||
| Omata 2012 (Omata et al. | Bovine, Agarose gel Type VII 20 % Fetal bovine serum; 0.85 mM L-ascorbic acid | 1.7-2.9* (15 %) | 1 | 6 | 22 | 132 | + E-modulus | ||
| Hung 2004 (Hung et al. | Bovine, Agarose gel Type VII 10 % Fetal bovine serum; growth factor: TGF-β1, IGF-1 | 0.6-1.2* (10 %) | 1 | 3 | 3 | 9 | + aggrecan | = aggregate modulus | |
| 3 | 20 | 60 | + E-modulus | ||||||
| + aggregate modulus | |||||||||
| Nicodemus 2010 (Nicodemus and Bryant | Young bovine, Hydrogel polyethylene glycol, 5 % Fetal bovine serum; 50 mg/L L-ascorbic acid | 1.2-2.4* (20 %) | 0.3 | 24 | 7 | 168 | + GAG | + aggrecan | |
| - collagen II | |||||||||
| - MMP-3 | |||||||||
| = MMP-13 | |||||||||
| 6 | 7 | 42 | = GAG | = aggrecan | |||||
| + collagen II | |||||||||
| + MMP-3, −13 | |||||||||
| Waldman 2004 (Waldman et al. | Bovine, Monolayer on top of calcium polyphosphate mesh, 5 % Fetal bovine serum | 0.3-0.6* (5 %) | 1 | .1 (400 cycles) | 3.5 | 0.5 | = PG synthesis | ||
| ++ coll. synthesis | |||||||||
| 0.6-1.2* (10 %) | ++ PG synthesis | ||||||||
| 1.2-2.4* (20 %) | = coll. synthesis | ||||||||
| 0.3-0.6* (5 %) | 0.6 (2000 cycles) | 3.5 | 2 | = PG synthesis | |||||
| + coll. synthesis | |||||||||
| 0.6-1.2* (10 %) | + PG synthesis | ||||||||
| 1.2-2.4* (20 %) | = coll. synthesis | ||||||||
| 0.3-0.6* (5 %) | 1 | 0.1 | 7 | 1 | = PG synthesis | = E-modulus | |||
| = coll. synthesis | |||||||||
| 0.1 | 14 | 2 | + PG synthesis | + E-modulus | |||||
| + coll. synthesis | |||||||||
| De Croos 2006 (De Croos et al. | Bovine, Monolayer on top of calcium polyphosphate mesh 5 % Fetal bovine serum | 0.001 | 1 | <1 h | 1 | <1 h | + PG synthesis ^ | + aggrecan ** | |
| + coll. synthesis ^ | + collagen II ** | ||||||||
| + MMP-3, −13 |
Results on changes in cellular and/or signaling response to BMMSC cultivated constructs under hydrostatic compression (Fig. 2). Sox9 is the gene that regulates chondrogenic differentiation; h is hours; h/day is hours per day; − is decrease or inhibition; and + is increase; ++ is highest increase; = is no change or status quo
| Study | Cell source, cultivated construct, additive(s) | Magnitude (MPa) | Freq (Hz) | Loading (h/day) | Loading (# days) | Loading (total h) | Culture composition (change -, =, +) | mRNA response (change -, =, +) |
|---|---|---|---|---|---|---|---|---|
| Mesh | ||||||||
| Wagner 2008 (Wagner et al. | Human BMMSC, Mesh Collagen Type 1 50 mg/mL bovine serum albumin; 50 μg/mL L-ascorbic acid; 10−9 M dexamethasone | 1 | 1 | 4 | 10 | 40 | + proteoglycan | + Sox9 |
| + aggrecan | ||||||||
| + collagen II | ||||||||
| Luo 2007 (Luo and Seedhom | Ovine BMMSC, Mesh non-woven filamentous plasma-treated polyester 10 % Fetal bovine serum; 50 μg/mL ascorbic acid; 10−7 M dexamethasone | 0.1 | 0.25 | 0.5 | 7 | 3.5 | + GAG | |
| = collagen | ||||||||
| 0.5 | 10 | 5 | ++ GAG | |||||
| + collagen | ||||||||
| Gel | ||||||||
| Miyanishi 2006a (Miyanishi et al. | Human BMMSC, Aggregate pellet 1.25 mg/mL bovine serum albumin; 50 μg/mL ascorbic acid; 10−7 M dexamethasone | 0.1 | 1 | 4 | 14 | 56 | = sGAG | + Sox9 |
| + aggrecan | ||||||||
| = collagen II | ||||||||
| 1 | + sGAG | ++ Sox9 | ||||||
| + aggrecan | ||||||||
| = collagen II | ||||||||
| 10 | ++ sGAG | ++ Sox9 | ||||||
| ++ aggrecan | ||||||||
| + collagen II | ||||||||
| Miyanishi 2006b (Miyanishi et al. | Human BMMSC, Aggregate pellet 1.25 mg/mL bovine serum albumin; 50 cpg/mL ascorbic acid; 10−7 M dexamethasone | 10 | 1 | 4 | 14 | 56 | + Sox9 | |
| + aggrecan | ||||||||
| + collagen II | ||||||||
| Angele 2003 (Angele et al. | Human BMMSC, Aggregate pellet 10 % Fetal bovine serum | 5.03 | 1 | 4 | 1 | 4 | = proteoglycan | |
| = collagen | ||||||||
| 4 | 7 | 28 | + proteoglycan | |||||
| + collagen | ||||||||
| Finger 2007 (Finger et al. | Human BMMSC, Agarose gel Type VII Growth medium Cambrex | 7.5 | 1 | 4 | 14 | 56 | = Sox9 | |
Fig. 2Difference between hydrostatic compression (left) and direct compression (right). The arrows indicate the loading direction